ALX Oncology Appoints Barbara Klencke as Interim Chief Medical Officer.

ALX Oncology has appointed Dr. Barbara Klencke as Interim Chief Medical Officer, replacing Alan Sandler, who resigned from the position. Dr. Klencke is an experienced clinical leader with a track record in oncology drug development and currently serves on ALX Oncology's Board of Directors. She will step down from the Board to join the company as Interim Chief Medical Officer.

ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology company specializing in cancer therapies, has announced the appointment of Dr. Barbara Klencke as Interim Chief Medical Officer (CMO), effective immediately. Dr. Klencke will replace Dr. Alan Sandler, who resigned from the position and will return to his role as a Director on the company's Board of Directors.

Dr. Klencke brings extensive experience in oncology drug development, having served in various executive leadership roles at biotech companies such as Sierra Oncology (acquired by GSK) and Genentech. She has been an ALX Oncology Board member since January 2025 and has witnessed firsthand the progress of the company's pipeline, including the evorpacept and ALX2004 clinical programs. Dr. Klencke's appointment is seen as a strategic move to accelerate the development and commercialization of ALX Oncology's innovative cancer therapies.

"Dr. Barbara Klencke’s extensive expertise in driving cancer innovation is evidenced by her substantial contributions to the development and approval of numerous first-in-class therapies," said Jason Lettmann, CEO of ALX Oncology. "Her immediate availability and deep R&D expertise position her well to lead the execution of our Company’s near and longer-term milestones."

Evorpacept, ALX Oncology's lead therapeutic candidate, has shown potential to serve as a cornerstone therapy in immuno-oncology. It is currently being evaluated across multiple clinical trials for various cancer indications. ALX2004, a novel EGFR-targeted antibody-drug conjugate, entered Phase 1 trials in August 2025.

Dr. Klencke's appointment is part of ALX Oncology's ongoing efforts to advance its pipeline of novel therapies designed to treat cancer and extend patients' lives. The company's focus on delivering clinically meaningful innovation to patients in need aligns with Dr. Klencke's commitment to driving cancer innovation.